New drug tested to make risky cancer transplants safer
NCT ID NCT04395222
Summary
This study is testing if a drug called tocilizumab can be used instead of another standard drug during a specific type of bone marrow transplant. The goal is to help patients' new immune systems recover faster and reduce serious complications like graft failure and graft-versus-host disease. It is for adults with blood cancers who need a transplant but lack a perfectly matched donor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Weill Cornell Medical College
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.